Researchers from Japan have suggested several factors, namely younger age at DMARD* therapy initiation and low serum C-reactive protein (CRP) levels, as factors that may predict successful down-titration of biologic DMARDs in patients with rheumatoid arthritis.
Patients with rheumatoid arthritis (RA) who are overweight or obese have a higher degree of histologically-proven follicular synovitis. Furthermore, body mass index (BMI) appears to impact response to treatment in these patients, according to a study presented at the annual meeting of the ACR/ARHP* held in San Diego, California, US.
Women who temporarily or permanently stop taking bisphosphonates (drug holiday) for an extended period of time may have an increased risk of hip fractures, findings from a recent population-based study revealed.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.